U.S. Hospital Respiratory Care Devices Market to USD 12.10B

Market Outlook

The U.S. Hospital Respiratory Care Devices Market is projected to reach USD 12.10 billion by 2032, expanding at a CAGR of 9.97% during the forecast period 2027–2032. The market was valued at USD 6.84 billion in 2026, following expansion from USD 5.36 billion in 2023 to USD 5.79 billion in 2024 and USD 6.29 billion in 2025. Historical analysis covers 2023–2025, the base year is 2026, and all monetary values in this report are expressed in USD billions.

The U.S. hospital respiratory care devices industry represents a clinically essential part of acute and critical care infrastructure. It includes invasive and non-invasive ventilators, high-flow oxygen systems, oxygen delivery equipment, nebulization and aerosol therapy devices, humidification systems, airway-clearance and suction equipment, respiratory monitoring platforms, diagnostic respiratory systems, interfaces, circuits, and associated hospital-use consumables. The scope excludes respiratory devices primarily sold for routine home care, consumer sleep therapy, or long-term domiciliary oxygen use unless the equipment forms part of an acute hospital respiratory pathway.

The demand base is unusually resilient because respiratory support is required across intensive care, emergency medicine, surgery, post-anesthesia recovery, neonatal and pediatric intensive care, step-down units, medical wards, infectious-disease management, and cardiopulmonary care. The United States has approximately 6,100 hospitals, more than 907,000 staffed hospital beds, and around 35.7 million hospital admissions annually, creating a large installed base for respiratory capital equipment and recurring demand for circuits, interfaces, humidification products, filters, oxygen-delivery components, suction products, aerosol systems, and monitoring consumables.

Clinical demand is supported by a significant respiratory disease burden. Approximately 4.2% of U.S. adults had been diagnosed with COPD, emphysema, or chronic bronchitis in 2024, while COPD alone caused more than 141,000 deaths in 2023. Asthma affects approximately 27.8 million people in the United States, including around 23 million adults, while nearly 11.8 million people with current asthma experienced at least one asthma attack during 2023. Acute respiratory infections add substantial seasonal pressure. The 2024–2025 influenza season generated approximately 710,000 U.S. hospitalizations, while RSV and COVID-19 contributed hundreds of thousands of additional hospital admissions.

Hospital respiratory procurement is consequently shifting from emergency capacity expansion toward fleet modernization, reliability, interoperability, infection-control performance, automated ventilation, high-flow therapy, patient-specific respiratory support, and integrated physiologic monitoring. The next investment cycle is increasingly determined by total respiratory-care economics rather than acquisition price alone. Hospitals favor systems that can reduce ventilation days, support earlier extubation, simplify respiratory therapist workflows, lower alarm burden, reduce device downtime, standardize equipment across departments, and provide measurable clinical and operational benefits.

The strongest value expansion through 2032 will occur in high-flow nasal oxygen systems, advanced non-invasive ventilation, lung- and diaphragm-protective ventilation modes, connected respiratory monitoring, neonatal ventilation technologies, intelligent oxygen titration, and digitally integrated respiratory workflows. Conventional ventilators will remain the largest equipment category, but growth will increasingly come from how effectively manufacturers integrate therapy delivery, sensing, analytics, accessories, and clinical workflow support.

Introduction

According to the U.S. Hospital Respiratory Care Devices Market Report, hospital respiratory care is moving from a collection of standalone devices toward an integrated acute-care technology ecosystem. Respiratory departments historically operated separate ventilators, pulse oximeters, capnography devices, nebulizers, oxygen-delivery systems, humidifiers, suction equipment, and pulmonary diagnostic tools. Major U.S. health systems are now increasingly evaluating these technologies as connected elements of a patient pathway extending from the emergency department through ICU stabilization, mechanical ventilation, weaning, step-down respiratory support, and discharge planning.

The market benefits from one of the world’s largest acute-care infrastructures. U.S. hospitals manage tens of millions of admissions annually, while emergency departments, operating rooms, ICUs, NICUs, PICUs, and respiratory therapy departments create substantial recurring utilization. Hospital capital purchasing is also supported by overall U.S. healthcare expenditure exceeding USD 5.3 trillion in 2024, demonstrating the financial scale of the care-delivery system within which respiratory products are purchased.

Acute respiratory failure remains one of the most resource-intensive clinical conditions managed inside hospitals. Severe pneumonia, sepsis, COPD exacerbation, asthma, trauma, postoperative respiratory compromise, neurological disease, heart failure, neuromuscular conditions, influenza, RSV, and COVID-19 can all require escalating levels of oxygen therapy or ventilatory support. During the 2024–2025 influenza season, older adults aged 65 years and above represented approximately 57% of influenza-related hospitalizations, reinforcing the connection between aging demographics and hospital respiratory utilization.

The industry is also shaped by respiratory therapist availability. Hospital systems operating large ventilator fleets must balance increasing clinical complexity against respiratory therapy staffing pressure. Procurement committees therefore increasingly favor automation, standardized user interfaces, integrated decision support, closed-loop or semi-automated features, easier circuit management, remote connectivity, and devices that reduce setup and monitoring burden.

Another defining characteristic is replacement-cycle sensitivity. Ventilator fleets are long-lived capital assets, but hospitals cannot indefinitely defer replacement where cybersecurity, software support, parts availability, regulatory actions, service-contract expiration, or clinical limitations increase risk. Recent manufacturer exits, recalls, corrections, and changes in product-support timelines are causing health systems to reassess vendor concentration and fleet resilience. Procurement decisions increasingly consider manufacturer stability, field-service capacity, software lifecycle, cybersecurity, consumables availability, and ability to maintain critical equipment throughout a seven-to-ten-year ownership period.

Over 2027–2032, hospital respiratory care will become more data-driven and acuity-adaptive. Rather than treating invasive ventilation as a standalone endpoint, hospitals will increasingly deploy a continuum encompassing conventional oxygen, high-flow therapy, non-invasive ventilation, invasive ventilation, advanced monitoring, airway clearance, and structured liberation from mechanical support. Vendors able to operate across several stages of this respiratory pathway will gain strategic advantage.

Key Market Drivers: What Is Fueling the U.S. Hospital Respiratory Care Devices Market?

The first major driver is the persistent burden of chronic and acute respiratory disease. COPD remains one of the leading causes of mortality in the United States, with disease prevalence increasing sharply among older adults. Among people aged 45 and above, COPD prevalence reached approximately 7.0% in 2024, while prevalence among older adults in nonmetropolitan areas can reach substantially higher levels. These patients generate recurring emergency visits and hospital admissions for exacerbations requiring oxygen supplementation, NIV, nebulized therapy, secretion management, blood-gas assessment, respiratory monitoring, and, in severe cases, invasive ventilation.

Asthma creates a second large demand pool. Approximately 8.4% of the U.S. population had current asthma in 2023, and more than 11 million people experienced an asthma attack during the year. Severe exacerbations continue to require emergency bronchodilator delivery, aerosol therapy, oxygen supplementation, continuous monitoring, and occasionally non-invasive or invasive ventilation. Hospital respiratory technology therefore remains central to managing severe asthma despite growing availability of outpatient biologic therapies.

The third driver is seasonal respiratory infection. The 2024–2025 influenza season was classified as high severity and resulted in approximately 710,000 hospitalizations. Among patients included in hospital surveillance, a meaningful proportion required intensive care and approximately 6% received invasive mechanical ventilation. RSV and COVID-19 created additional hospitalization volumes, with older adults, infants, and medically complex patients disproportionately represented. Hospitals consequently require sufficient respiratory surge capacity even outside pandemic conditions.

A fourth driver is the aging U.S. population. Adults aged 65 and above have substantially higher prevalence of COPD, pneumonia, heart failure, neuromuscular weakness, postoperative pulmonary complications, and severe respiratory viral disease. Older patients also have lower physiological reserve and greater likelihood of requiring oxygen escalation or ventilatory support during acute illness. This demographic shift supports long-term utilization of high-flow systems, NIV platforms, oxygen-delivery technologies, monitoring equipment, and critical-care ventilators.

A fifth driver is increased adoption of non-invasive respiratory support. U.S. clinicians increasingly attempt to stabilize appropriate patients without endotracheal intubation. High-flow nasal oxygen and NIV can provide clinically meaningful support in hypoxemic and hypercapnic respiratory failure while reducing complications associated with invasive ventilation when appropriate patient selection and monitoring are maintained. These therapies are expanding beyond traditional ICUs into emergency departments, step-down units, respiratory wards, and selected post-operative pathways.

Hospital capital replacement represents another important growth engine. The pandemic expanded ventilator inventories, but portions of that installed base are now moving toward structured replacement planning. At the same time, manufacturer portfolio changes and product-support sunsets are accelerating replacement decisions. Hospitals increasingly prefer current-generation platforms with standardized software, better alarm management, improved patient synchrony, integrated capnography or oxygen monitoring, transport capability, and easier connectivity to hospital information systems.

Finally, clinical labor economics is becoming an increasingly important purchasing driver. Respiratory therapists are responsible for large numbers of devices across multiple departments. Products that reduce manual titration, accelerate setup, standardize interfaces, automate routine adjustments, support remote visibility, and simplify preventive maintenance can generate value even when their acquisition cost is higher. For hospital executives, the key metric is increasingly total respiratory-care productivity per staffed bed rather than unit price alone.

Innovation in Focus: How Manufacturers Are Raising the Bar

Innovation in hospital respiratory care is increasingly directed toward individualized ventilation rather than simply greater pressure or flow capability. Advanced systems use pressure, flow, electrical activity, oxygenation, and respiratory mechanics data to improve patient-device synchrony and support lung-protective strategies. The objective is to provide sufficient respiratory support while reducing ventilator-induced lung injury, diaphragmatic dysfunction, oversedation, and prolonged ventilation.

Automated and semi-automated ventilation is one of the most important development areas. Intelligent algorithms can assist clinicians with pressure support, minute ventilation, oxygenation targets, weaning, and patient adaptation. These functions are particularly valuable in hospitals managing staffing constraints because they can reduce the number of repetitive manual adjustments required across large ventilated-patient populations. Their commercial value depends on usability, clinical evidence, transparency, and clinician confidence rather than automation alone.

High-flow nasal oxygen has developed into a major acute-care modality. Modern high-flow platforms provide warmed, humidified gas at precisely controlled flows and oxygen concentrations. The technology has become embedded in respiratory pathways for hypoxemic respiratory failure, post-extubation support, selected COPD patients, respiratory infections, and patients who require more support than conventional oxygen but may not yet require NIV or intubation. Through 2032, high-flow systems are expected to represent one of the fastest-growing hospital respiratory device categories.

Non-invasive ventilation is evolving through improved mask interfaces, leak compensation, synchronization algorithms, helmet-based approaches in selected centers, and closer integration with oxygen and high-flow therapy. Hospitals increasingly value platforms that allow movement across several respiratory-support levels without requiring an entirely different equipment ecosystem.

Respiratory monitoring is also moving beyond pulse oximetry. Capnography, transcutaneous gas monitoring, respiratory-rate analytics, advanced waveform analysis, electrical impedance technologies, ventilator-derived mechanics, and integrated bedside data are becoming more important. Continuous respiratory monitoring is particularly relevant in step-down units and post-operative care, where delayed recognition of deterioration can lead to emergency ICU transfer.

Neonatal and pediatric respiratory care remains a high-value innovation area because these patients require exceptionally precise pressure, volume, flow, and humidification control. Technologies that reduce volutrauma, barotrauma, airway injury, or oxygen toxicity are commercially attractive to tertiary pediatric centers and NICUs.

Connectivity and cybersecurity are becoming equally important. Hospitals increasingly require ventilators and respiratory devices to connect securely with patient-monitoring networks, clinical information systems, and electronic medical records. Procurement teams are demanding stronger software-maintenance policies, cybersecurity documentation, patching capability, and long-term technical support. Recent device corrections and cybersecurity-related respiratory product actions have reinforced the importance of lifecycle management as part of device quality.

Segmentation Insights

The U.S. Hospital Respiratory Care Devices Market is segmented on the basis of product type, therapy modality, clinical application, hospital department, patient group, and region.

By Product Type

Ventilators and Ventilation Systems

Ventilators and associated ventilation systems represented the largest product category, accounting for approximately USD 2.08 billion in 2026, or slightly above 30% of hospital respiratory care device revenue. The category includes intensive-care ventilators, non-invasive ventilators, transport ventilators, neonatal ventilators, ventilator interfaces, breathing circuits, expiratory filtration components, and selected ventilation accessories.

Demand remains concentrated in ICUs, emergency departments, NICUs, PICUs, and high-acuity transport pathways. The U.S. mechanical ventilator installed base is mature, meaning future value expansion depends more on fleet replacement, technology upgrades, accessory revenue, and premium ventilation capabilities than on simple unit expansion. By 2032, the ventilation category is expected to approach USD 3.60 billion, supported by advanced ventilation modes, replacement of aging fleets, improved connectivity, and respiratory surge-capacity requirements.

Oxygen Therapy and High-Flow Systems

Oxygen therapy and high-flow systems generated approximately USD 1.27 billion in 2026. This segment includes high-flow nasal oxygen systems, hospital oxygen concentrator applications, flowmeters, blenders, wall-connected oxygen-delivery equipment, cannulas, masks, high-flow interfaces, and associated oxygen-management technologies.

High-flow oxygen is the fastest-growing component because its clinical use has expanded substantially across respiratory failure, post-extubation management, emergency medicine, and step-down care. Unlike conventional oxygen therapy, high-flow systems require active flow generation, temperature control, and humidification, increasing device and consumable value per treated patient. The segment is positioned to exceed USD 2.4 billion by 2032, making it an increasingly strategic part of hospital respiratory portfolios.

Respiratory Monitoring and Diagnostic Devices

Respiratory monitoring and hospital respiratory diagnostics accounted for approximately USD 1.18 billion in 2026. The segment includes capnography, respiratory-rate monitoring, transcutaneous gas monitoring, bedside respiratory analytics, pulmonary function equipment used by hospital respiratory departments, spirometry platforms, and selected integrated respiratory surveillance systems.

The segment is being strengthened by concern over unrecognized respiratory deterioration outside the ICU. Hospitals are extending respiratory monitoring into emergency departments, procedural recovery areas, step-down units, and medical-surgical floors. Rising opioid-related respiratory risk, postoperative monitoring requirements, and efforts to reduce rapid-response events support adoption. Advanced monitoring is also becoming increasingly linked with alarm analytics and centralized surveillance.

Airway Clearance and Suction Devices

Airway-clearance and suction systems represented approximately USD 0.83 billion in 2026. This category includes hospital suction equipment, secretion-management technologies, mechanical insufflation-exsufflation systems, oscillatory airway-clearance systems, percussive ventilation technologies, cough-assist devices, and related disposables.

The category is clinically important in ventilated patients, neuromuscular disease, spinal cord injury, bronchiectasis, cystic fibrosis, postoperative pulmonary care, and patients with impaired secretion clearance. Demand is supported by the need to prevent mucus plugging, atelectasis, secondary infection, and respiratory deterioration. Hospital value analysis increasingly focuses on whether airway-clearance technology can reduce escalation to bronchoscopy, shorten therapy sessions, or support earlier mobilization.

Aerosol and Nebulization Systems

Hospital aerosol and nebulization devices generated approximately USD 0.72 billion in 2026. Products include jet nebulizers, vibrating-mesh nebulizers, continuous aerosol systems, medication-delivery interfaces, ventilator-compatible aerosol systems, and associated disposables.

Severe asthma and COPD exacerbations remain major use cases, while aerosolized medications are also administered to mechanically ventilated patients. Approximately 27.8 million Americans have current asthma, creating a large underlying population from which acute hospital exacerbations arise. Newer mesh-nebulization technologies are gaining preference in higher-acuity settings because they can improve drug-delivery efficiency and integrate more effectively with respiratory circuits.

Humidification, Circuits and Respiratory Consumables

Humidification systems, breathing circuits, interfaces, filters, connectors, and related hospital respiratory consumables accounted for approximately USD 0.76 billion in 2026. While individual product prices are lower than those of capital equipment, the segment benefits from recurring replacement and high procedure frequency.

Consumables are strategically important because they create recurring revenue around an installed device base. Hospitals increasingly standardize circuits, filters, NIV interfaces, humidification chambers, and oxygen-delivery components through enterprise contracts. Infection prevention, compatibility, supply reliability, ease of setup, and waste reduction are important purchasing considerations.

By Therapy Modality

Invasive Mechanical Ventilation

Invasive mechanical ventilation represented approximately USD 1.86 billion in 2026 and remains the highest-value respiratory therapy modality. Demand is concentrated among patients with severe respiratory failure, ARDS, sepsis, major trauma, neurologic impairment, postoperative complications, and severe respiratory infections.

Although clinical practice increasingly favors avoiding unnecessary intubation, invasive ventilation remains indispensable. The commercial opportunity is shifting toward lung-protective ventilation, automated support, improved patient synchrony, integrated weaning tools, advanced humidification, and technologies that reduce ventilator-associated complications.

Non-Invasive Positive Pressure Ventilation

Non-invasive positive pressure ventilation accounted for approximately USD 1.29 billion in 2026. NIV is especially important in COPD exacerbations, cardiogenic pulmonary edema, selected hypercapnic respiratory failure, post-extubation support, and patients who are poor candidates for immediate invasive ventilation.

COPD’s substantial U.S. burden supports recurring hospital NIV utilization. COPD generated approximately 854,000 emergency department visits with COPD as the primary diagnosis in available national data, highlighting the scale of acute exacerbation management. Hospitals increasingly prefer NIV systems with effective leak compensation, comfortable interfaces, strong alarm management, and ability to operate across multiple care areas.

High-Flow Nasal Oxygen

High-flow nasal oxygen generated approximately USD 0.92 billion in 2026 and represents the fastest-expanding respiratory support modality. Use has expanded markedly following widespread hospital experience during the COVID-19 era.

The technology is now used in hypoxemic respiratory failure, respiratory infections, post-extubation support, emergency care, and selected immunocompromised or high-risk patients. Its growth is reinforced by ease of application relative to NIV and the ability to provide high flows with active humidification.

Conventional Oxygen Delivery

Conventional oxygen delivery accounted for approximately USD 0.84 billion in 2026. Nasal cannulas, oxygen masks, Venturi systems, flow controllers, oxygen blenders, and wall-gas accessories remain essential in virtually every U.S. acute-care hospital.

The segment has a mature growth profile but extremely broad utilization. Future differentiation will come from controlled oxygen delivery, improved monitoring, disposable optimization, infection-control design, and systems that allow efficient escalation from conventional oxygen to high-flow support.

Aerosol and Humidified Respiratory Therapy

Aerosol and humidified therapy represented approximately USD 0.89 billion in 2026. The category serves asthma, COPD, bronchospasm, mechanically ventilated patients, tracheostomy care, and secretion-management pathways.

Vibrating-mesh nebulization and advanced active humidification are gaining share because hospitals increasingly evaluate drug deposition, circuit integrity, condensate management, infection-control risk, and respiratory therapist workflow as part of technology selection.

Respiratory Monitoring and Airway-Support Therapy

Respiratory monitoring and airway-support applications accounted for approximately USD 1.04 billion in 2026. This segment includes technologies supporting early recognition of respiratory decline, airway clearance, secretion management, assisted cough, and respiratory surveillance.

Growth is closely tied to hospitals’ efforts to identify deterioration before emergency intubation or ICU transfer. Continuous monitoring in step-down and general-care units will therefore become an increasingly important purchasing area.

By Clinical Application

Acute Respiratory Failure and ARDS

Acute respiratory failure and ARDS represented approximately USD 1.82 billion in 2026, making them the largest clinical application for hospital respiratory devices. These patients consume high levels of respiratory resources because therapy can include high-flow oxygen, NIV, invasive ventilation, advanced monitoring, humidification, suction, and prolonged consumable use.

The commercial opportunity extends beyond ventilator placement. Hospitals increasingly focus on complete respiratory pathways including lung-protective ventilation, prone-positioning support, secretion management, oxygen titration, monitoring, and structured weaning.

COPD Exacerbations

COPD-related hospital respiratory care accounted for approximately USD 1.28 billion in 2026. Diagnosed COPD affected roughly 4.2% of U.S. adults in 2024, and prevalence rises substantially with age. Among adults aged 75 and older, diagnosed COPD prevalence is materially higher than among younger groups.

COPD exacerbations create demand for controlled oxygen, NIV, nebulized bronchodilators, high-flow systems, secretion management, capnography, and, in severe cases, invasive ventilation. NIV adoption is particularly important because it can prevent intubation in appropriately selected hypercapnic patients.

Postoperative, Trauma and Perioperative Respiratory Support

Postoperative and trauma-related respiratory applications accounted for approximately USD 0.96 billion in 2026. General anesthesia, major abdominal or thoracic surgery, trauma, neurological procedures, and prolonged immobilization create risk of hypoventilation, atelectasis, secretion retention, and respiratory compromise.

Hospitals use oxygen therapy, respiratory monitoring, incentive and assisted respiratory support, airway-clearance technologies, NIV, and mechanical ventilation across OR, PACU, trauma ICU, and surgical wards. Growing emphasis on enhanced recovery pathways supports technologies that facilitate earlier extubation and mobilization.

Respiratory Infection Management

Influenza, RSV, COVID-19, pneumonia, and other respiratory infections represented approximately USD 1.04 billion in 2026 hospital respiratory device demand. The 2024–2025 influenza season alone generated approximately 710,000 hospitalizations, while RSV was associated with approximately 190,000–350,000 hospitalizations and COVID-19 with approximately 290,000–450,000 hospitalizations during broadly comparable respiratory surveillance periods.

This burden reinforces the need for flexible surge capacity. Hospitals value respiratory systems that can be deployed rapidly across departments and scaled from oxygen supplementation through invasive ventilation.

Asthma and Acute Bronchospasm

Asthma and bronchospasm applications represented approximately USD 0.63 billion in 2026. Approximately 27.8 million Americans have current asthma, with around 42% of individuals with current asthma experiencing at least one attack in 2023.

Emergency departments remain the primary acute-care entry point for severe exacerbations. Aerosol therapy, oxygen administration, monitoring, and NIV are central device categories. Pediatric demand is especially relevant because asthma remains one of the most common chronic respiratory diseases among children.

Neonatal, Pediatric, Neuromuscular and Other Applications

Neonatal and pediatric respiratory care represented approximately USD 0.57 billion in 2026, while neuromuscular and other respiratory-support applications contributed approximately USD 0.54 billion.

Infants have particularly high vulnerability to RSV and respiratory distress, while premature neonates frequently require carefully controlled respiratory support. Neuromuscular disease creates demand for NIV, cough assistance, secretion management, and respiratory monitoring. These applications are smaller by patient count but disproportionately high in device sophistication and clinical intensity.

By Hospital Department

Intensive Care Units

ICUs represented approximately USD 3.10 billion in 2026, accounting for more than 45% of the market. Critical-care units purchase the highest-acuity ventilators, high-flow systems, NIV devices, humidification equipment, airway-clearance systems, suction technologies, and advanced respiratory monitoring.

ICU procurement is heavily influenced by reliability, clinical performance, standardization, service coverage, training, cybersecurity, and integration with existing monitoring platforms. Capital committees increasingly prefer fewer, more scalable platforms capable of supporting adult, pediatric, and specialized respiratory workflows.

Emergency Departments

Emergency departments accounted for approximately USD 1.07 billion in 2026. ED respiratory technology must support rapid escalation from oxygen delivery to high-flow, NIV, or invasive ventilation.

COPD exacerbations, asthma, pneumonia, sepsis, overdose, trauma, heart failure, and respiratory viral disease all generate demand. Portability, rapid setup, intuitive operation, and compatibility with transport workflows are particularly important.

General Wards and Step-Down Units

General medical and step-down units represented approximately USD 1.12 billion in 2026. Growth in this setting is being supported by high-flow therapy, continuous respiratory monitoring, capnography, oxygen-management systems, and selected NIV applications.

Hospitals are increasingly interested in technologies that allow respiratory patients to remain safely outside the ICU, because ICU capacity carries materially higher labor and infrastructure costs. Products capable of supporting controlled acuity migration therefore have strong economic relevance.

Operating Rooms and Post-Anesthesia Care

Operating rooms and PACUs generated approximately USD 0.71 billion in 2026 in hospital respiratory care demand. This includes airway support, respiratory circuits, oxygen delivery, post-extubation support, capnography, suction, and respiratory monitoring.

Postoperative respiratory depression is an important patient-safety consideration, especially among older adults, patients with obesity, sleep-disordered breathing, or high opioid exposure. Continuous respiratory monitoring and earlier use of NIV or high-flow support are therefore gaining relevance.

NICU and PICU

NICU and PICU respiratory devices accounted for approximately USD 0.56 billion in 2026. These departments require highly specialized ventilators, high-flow systems, oxygen blenders, humidification, neonatal interfaces, respiratory monitoring, and resuscitation equipment.

The relatively small patient population supports substantial device value because neonatal respiratory management requires precision, specialized disposables, and high clinical reliability.

Respiratory Therapy and Pulmonary Diagnostic Departments

Dedicated respiratory therapy and pulmonary-function departments represented approximately USD 0.28 billion in 2026. Although smaller by direct device revenue, these departments influence hospital-wide purchasing decisions because respiratory therapists manage ventilator fleets, aerosol systems, oxygen technology, airway-clearance equipment, and related consumables.

By Patient Group

Adults Aged 18–64 Years

Adults aged 18–64 accounted for approximately USD 3.19 billion in 2026. Demand is driven by severe respiratory infection, asthma, COPD, trauma, postoperative complications, sepsis, neurological disease, obesity-related respiratory compromise, and other acute conditions.

This group represents the largest patient base by volume, while technology requirements vary significantly by underlying disease and acuity.

Adults Aged 65 Years and Above

Geriatric patients represented approximately USD 2.48 billion in 2026 and are expected to generate one of the fastest-growing patient-group revenue pools through 2032.

Older adults experience higher COPD prevalence, pneumonia risk, respiratory-virus hospitalization, cardiac-pulmonary interaction, frailty, and postoperative complications. During the high-severity 2024–2025 influenza season, people aged 65 years and above accounted for approximately 57% of hospitalizations. Aging demographics therefore materially increase utilization of oxygen therapy, NIV, mechanical ventilation, monitoring, and secretion-management technologies.

Pediatric Patients

Pediatric respiratory care accounted for approximately USD 0.70 billion in 2026. Asthma, RSV, pneumonia, congenital conditions, trauma, and acute respiratory failure are important demand drivers.

Pediatric hospitals and tertiary health systems require equipment with appropriate pressure and volume sensitivity, dedicated interfaces, accurate oxygen blending, and child-specific safety capabilities.

Neonatal Patients

Neonatal respiratory care represented approximately USD 0.47 billion in 2026. Preterm infants and critically ill newborns may require CPAP, high-flow therapy, non-invasive ventilation, invasive ventilation, oxygen blending, humidification, and continuous monitoring.

Product selection places exceptional emphasis on low tidal volumes, precise pressure control, minimal dead space, accurate leak compensation, and avoidance of oxygen-associated injury.

Regional Insights: Where the Market Is Growing Fastest

The U.S. Hospital Respiratory Care Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional performance differs according to population growth, hospital capacity, age distribution, COPD and asthma burden, rural access, respiratory-virus hospitalization, academic medical center density, health-system consolidation, and speed of adoption of high-acuity technology.

South

The South represented the largest regional market at approximately USD 2.48 billion in 2026, accounting for more than 36% of national revenue. The region includes Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, Maryland, Tennessee, Kentucky, Alabama, Mississippi, Louisiana, Arkansas, Oklahoma, West Virginia, Delaware, and the District of Columbia under commonly applied regional groupings.

The South combines high population scale with significant chronic respiratory disease burden. Many Southern states have elevated smoking history, COPD prevalence, obesity, cardiovascular disease, diabetes, and rural-health access challenges. This creates substantial demand for emergency respiratory stabilization, NIV, oxygen therapy, mechanical ventilation, and post-acute respiratory management.

Texas represents one of the largest individual state opportunities. Houston, Dallas-Fort Worth, San Antonio, and Austin contain major tertiary and academic hospital networks with large ICU footprints and sophisticated trauma, transplantation, cardiovascular, neonatal, and pulmonary programs. Texas hospitals are important purchasers of high-acuity ventilators, high-flow systems, respiratory monitoring, airway-management technologies, and enterprise respiratory consumables.

Florida is another critical state because of its large older adult population. Respiratory viral disease, COPD, pneumonia, heart failure, and postoperative respiratory compromise create sustained respiratory-care demand. Florida health systems also operate large numbers of acute-care facilities, supporting enterprise standardization opportunities for respiratory suppliers.

North Carolina, Georgia, Tennessee, and Virginia provide additional growth through population expansion and health-system investment. Major academic and referral centers in these states support adoption of advanced ventilation, neonatal respiratory care, high-flow therapy, and complex critical-care monitoring.

Mississippi, Alabama, Kentucky, West Virginia, Arkansas, and Louisiana present a different opportunity profile. Respiratory disease burden is high, but hospital resources and specialty access can be uneven. Vendors capable of combining reliable equipment, flexible financing, strong field service, clinician education, and scalable technology can compete effectively.

The South is projected to approach USD 4.5 billion by 2032. Growth will be supported by population expansion, aging demographics, high chronic respiratory disease burden, hospital network consolidation, and replacement of older respiratory technology.

West

The West represented approximately USD 1.63 billion in 2026 and is positioned to record the fastest regional growth through 2032. California is the dominant state market, followed by Washington, Arizona, Colorado, Oregon, Nevada, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii.

California combines a very large population with internationally recognized academic hospitals, integrated delivery networks, children’s hospitals, transplant centers, and technology-oriented healthcare systems. Hospitals in the state are comparatively receptive to connected monitoring, analytics, automated respiratory support, and technologies capable of reducing ICU resource utilization.

California is also important to suppliers because environmental factors can periodically increase respiratory demand. Wildfire smoke and air-quality events can worsen asthma and chronic lung disease, creating episodic pressure on emergency and respiratory services.

Arizona and Nevada are high-growth opportunities because of population growth and aging demographics. Older population groups increase demand for COPD and pneumonia care, NIV, oxygen therapy, and intensive respiratory support.

Washington, Oregon, Colorado, and Utah contain sophisticated integrated health systems that are receptive to enterprise technology standardization, digital connectivity, and clinical workflow redesign. These states can function as early adoption markets for advanced monitoring and respiratory automation.

Rural Western states such as Montana, Wyoming, Idaho, Alaska, and parts of New Mexico create opportunities for transportable respiratory equipment, reliable NIV, tele-enabled monitoring, and systems that can operate effectively across smaller hospitals connected to regional referral centers.

The West is expected to exceed USD 3.0 billion by 2032, supported by approximately 11% regional growth. Digital integration, high-flow adoption, connected respiratory surveillance, and population migration into Western metropolitan markets will support above-average expansion.

Northeast

The Northeast accounted for approximately USD 1.42 billion in 2026. The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Rhode Island, Maine, Vermont, and New Hampshire.

The Northeast has a mature but high-value hospital environment. It contains a dense concentration of academic medical centers, specialty children’s hospitals, research institutions, transplant programs, and high-acuity referral systems. Respiratory procurement therefore places strong emphasis on evidence, device sophistication, neonatal capabilities, infection control, data integration, and performance in complex patients.

New York is the largest state respiratory device market in the region. New York City alone contains numerous large academic and integrated systems managing significant critical-care, emergency, surgical, pulmonary, and pediatric volumes. The state’s previous pandemic experience also reinforced the importance of ventilator preparedness and flexible oxygen infrastructure.

Massachusetts has disproportionate influence relative to population because Boston’s academic medical ecosystem frequently participates in respiratory trials, technology evaluation, and development of critical-care protocols. Suppliers that secure adoption in major Massachusetts centers can benefit from broader clinical credibility.

Pennsylvania and New Jersey provide large and diversified demand across academic hospitals, regional health systems, community hospitals, and post-acute referral networks. Both states are important markets for NIV, mechanical ventilation, respiratory monitoring, and pulmonary diagnostic technologies.

New England states including Maine, New Hampshire, Vermont, Rhode Island, and Connecticut combine advanced referral centers with smaller community hospitals. Aging populations support respiratory demand, while lower-density areas increase the importance of reliable equipment and centralized clinical support.

The Northeast is expected to reach approximately USD 2.4 billion by 2032. Growth will be less population-driven than in the South or West but supported by premium technology adoption, aging demographics, academic innovation, and replacement of sophisticated installed equipment.

Midwest

The Midwest represented approximately USD 1.31 billion in 2026. Major state markets include Illinois, Ohio, Michigan, Minnesota, Indiana, Wisconsin, Missouri, Iowa, Kansas, Nebraska, North Dakota, and South Dakota.

The Midwest provides a stable base of critical-care demand supported by major urban referral centers, broad community hospital networks, and significant chronic cardiopulmonary disease burden. Chicago, Cleveland, Detroit, Minneapolis-St. Paul, Indianapolis, Milwaukee, St. Louis, Kansas City, and Columbus support large tertiary hospital markets.

Illinois is the largest respiratory device market in the region due to Chicago’s extensive provider infrastructure. Ohio is strategically important because of its concentration of internationally recognized hospital systems and high-acuity critical-care programs. Michigan supports substantial demand for respiratory support related to chronic lung disease, cardiovascular disease, surgery, and emergency care.

Minnesota combines strong clinical institutions with a mature medical-device ecosystem. Wisconsin, Indiana, and Missouri represent sizeable markets for ICU ventilation, oxygen therapy, NIV, and respiratory monitoring.

The region also contains substantial rural populations. National data indicate that among adults aged 45 and above, COPD prevalence can exceed 10% in nonmetropolitan areas, compared with substantially lower prevalence in large metropolitan centers. Rural respiratory disease burden creates demand for dependable equipment, transfer stabilization, NIV, oxygen delivery, transport ventilation, and tele-supported clinical models.

The Midwest is expected to reach approximately USD 2.1 billion by 2032. Growth will remain somewhat below the South and West, but hospital replacement cycles, aging populations, rural respiratory burden, and integrated delivery network purchasing will maintain durable demand.

Key Market Players

The U.S. Hospital Respiratory Care Devices Competitive Landscape is moderately consolidated in high-acuity ventilation and high-flow therapy but more fragmented across airway clearance, respiratory monitoring, aerosol therapy, oxygen delivery, and consumables.

The competitive environment is increasingly defined by installed-base strategy. Manufacturers benefit when capital equipment drives recurring purchases of circuits, humidification components, interfaces, filters, sensors, and service contracts. Hospital systems, however, are becoming more cautious about excessive dependence on a single supplier following recent recalls, product discontinuations, manufacturing exits, and supply-chain disruption.

The market is also becoming service-intensive. Clinical training, respiratory therapist education, equipment uptime, biomedical engineering support, cybersecurity, parts availability, software upgrades, and fleet-management capability are important components of contract awards.

Highly relevant participants in the U.S. Hospital Respiratory Care Devices Market include:

Philips Healthcare
Drägerwerk AG & Co. KGaA
Hamilton Medical
Getinge AB
Fisher & Paykel Healthcare
ResMed
GE HealthCare
Medtronic
Baxter International
Masimo Corporation
ICU Medical
Nihon Kohden
ZOLL Medical Corporation
Teleflex Incorporated
Air Liquide Healthcare

Philips remains strategically relevant across respiratory support despite major regulatory and portfolio challenges affecting its respiratory business. Dräger, Hamilton Medical, and Getinge are particularly important in high-acuity hospital ventilation. Fisher & Paykel Healthcare has strong exposure to high-flow nasal therapy, humidification, and respiratory interfaces. ResMed remains an important non-invasive respiratory technology participant.

GE HealthCare, Masimo, and Nihon Kohden influence the respiratory market through patient monitoring, respiratory surveillance, gas monitoring, and integrated acute-care technologies. Baxter participates through hospital respiratory therapy and airway-clearance assets, while ICU Medical, Teleflex, ZOLL, Air Liquide Healthcare, and Medtronic retain relevant positions across ventilation support, respiratory consumables, airway management, monitoring, and related acute-care products.

Medtronic’s decision to exit new ventilator manufacturing has particular strategic implications. Existing Puritan Bennett ventilators remain part of the U.S. installed base, and service support continues according to product-specific timelines, but hospitals replacing these fleets must increasingly migrate toward alternative platforms. This creates a meaningful share-transfer opportunity for active ventilation manufacturers through the forecast period.

Competitive share gains will increasingly depend on the ability to demonstrate reliable hardware, intuitive interfaces, advanced ventilation performance, consumable availability, favorable service economics, cybersecurity, interoperability, training capacity, and long-term product support.

Recent Developments

The U.S. respiratory care market has entered an unusually important equipment-lifecycle transition. A series of regulatory actions, product corrections, recalls, manufacturer portfolio decisions, and clinical technology upgrades is influencing how hospitals assess respiratory suppliers.

One of the most consequential developments has been Philips Respironics’ regulatory situation. Following the large-scale recall involving ventilators, CPAP, and bilevel systems, a federal consent decree placed restrictions on manufacturing and sale of certain new products from affected U.S. facilities. The original recall affected approximately 15 million devices worldwide, making it one of the most significant respiratory-device quality events in recent industry history. For hospital procurement committees, the impact goes beyond the affected devices; supplier quality systems and remediation capacity have become more prominent components of respiratory contract evaluation.

Medtronic separately moved to exit ventilator manufacturing. Production of major Puritan Bennett ventilator platforms was discontinued, while service and parts support will continue for defined periods. Because Puritan Bennett systems have historically maintained a meaningful U.S. hospital installed base, replacement of these devices creates a multiyear competitive opportunity for Hamilton Medical, Dräger, Getinge, and other active critical-care ventilation suppliers.

Ventilator safety remained a material industry issue during 2025. FDA actions affected products from Hamilton Medical, Getinge’s Maquet critical-care business, Philips Respironics, Baxter, and other respiratory suppliers. These actions reinforce the importance of fleet diversity, biomedical engineering preparedness, preventive maintenance, software control, alarm management, and rapid vendor field support.

Getinge advanced its Servo-u platform in 2025 through introduction of Neural Pressure Support and NIV Neural Pressure Support. These modes build on neurally controlled ventilation concepts and reflect the market’s broader movement toward respiratory assistance that responds more closely to patient effort. Lung protection is increasingly being complemented by concern over diaphragm protection and avoidance of excessive or insufficient ventilatory assistance.

Baxter’s permanent removal of the Life2000 ventilation system following cybersecurity concerns also demonstrates how software and cybersecurity have become clinically relevant respiratory-device risks. Hospitals are increasingly evaluating whether connected respiratory platforms have well-defined cybersecurity update processes and whether manufacturers can provide sustained software support.

High-flow respiratory therapy continues to expand as hospitals formalize protocols defining when patients should move from conventional oxygen to high-flow therapy, NIV, or invasive ventilation. This creates opportunities not only for flow-generating systems but also for heated humidification, disposable circuits, cannulas, oxygen blending, and monitoring.

Respiratory monitoring is similarly receiving more attention outside intensive care. Hospitals increasingly recognize that continuous pulse oximetry alone may not identify all deteriorating patients early enough. Capnography, respiratory-rate analytics, centralized monitoring, and other respiratory surveillance technologies are therefore being incorporated into selected postoperative, step-down, and opioid-risk pathways.

The strategic direction through 2032 will consequently be characterized by fewer purely standalone devices and greater demand for integrated respiratory ecosystems combining therapy delivery, monitoring, consumables, data, technical support, and clinical workflow services.

Conclusion

The U.S. Hospital Respiratory Care Devices Market is positioned to expand from USD 6.84 billion in 2026 to USD 12.10 billion by 2032, advancing at a 9.97% CAGR during 2027–2032. Historical market value increased from USD 5.36 billion in 2023 to USD 5.79 billion in 2024 and USD 6.29 billion in 2025 as hospitals rebuilt respiratory inventories, expanded high-flow therapy, modernized monitoring, and resumed structured capital-equipment replacement.

The market’s long-term fundamentals are supported by large hospital infrastructure, tens of millions of annual admissions, persistent COPD and asthma burden, aging demographics, recurrent respiratory-virus hospitalization, complex surgical volumes, and the indispensable role of respiratory support in critical care.

The strongest commercial opportunities will not necessarily come from adding more conventional ventilator capacity. Value creation is shifting toward high-flow nasal oxygen, advanced NIV, intelligent ventilation, connected respiratory monitoring, neonatal respiratory technologies, improved humidification, airway-clearance platforms, and recurring consumables associated with large installed bases.

Hospitals will increasingly evaluate respiratory technologies through clinical and operational outcomes. Important purchasing questions will include whether a platform can improve patient-device synchrony, shorten time on respiratory support, reduce ICU escalation, enable earlier weaning, lower alarm burden, simplify respiratory therapist workflows, reduce device downtime, and maintain cybersecurity and service reliability over its entire lifecycle.

Regionally, the South will remain the largest market, driven by population size, older demographics, chronic respiratory burden, and expanding health systems. The West will generate the fastest growth, supported by technology adoption and population expansion. The Northeast will remain a premium high-acuity market, while the Midwest will provide stable demand supported by large health systems, respiratory disease burden, and rural-care requirements.

For respiratory device manufacturers, distributors, investors, health systems, and market-entry teams, the central strategic issue is no longer whether hospital respiratory technology remains essential. The more important question is how respiratory support will migrate across acuity levels and which manufacturers can create a dependable continuum from conventional oxygen and high-flow therapy through NIV, invasive ventilation, monitoring, airway management, and recovery.

Suppliers capable of combining differentiated technology with clinical evidence, reliable consumables, respiratory therapist workflow efficiency, cybersecurity, nationwide service infrastructure, and compelling total-cost-of-ownership economics will be best positioned to capture the next phase of growth in the U.S. Hospital Respiratory Care Devices Market.